Predict your next investment

Immune-Onc Therapeutics company logo
HEALTHCARE | Biotechnology
immune-onc.com

See what CB Insights has to offer

Founded Year

2016

Stage

Series B - II | Alive

Total Raised

$81.32M

Last Raised

$40M | 10 mos ago

About Immune-Onc Therapeutics

Immune-Onc Therapeutics is a privately held cancer immunotherapy company dedicated to the discovery and development of biologic treatments for cancer patients. The company aims to translate scientific insights in the tumor microenvironment and immune suppressive pathways to develop biotherapeutics.

Immune-Onc Therapeutics Headquarter Location

795 San Antonio Rd

Palo Alto, California, 94303,

United States

650-460-8898

Latest Immune-Onc Therapeutics News

Immune-Onc Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Jan 10, 2022

January 10, 2022 11:00 AM Eastern Standard Time PALO ALTO, Calif.--( BUSINESS WIRE )--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced the Company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 12:30 PM PST/3:30 PM EST, during the Private Companies Track 2. Charlene Liao, Ph.D., chief executive officer of Immune-Onc, will provide a corporate overview, including recent clinical development progress and anticipated milestones for 2022 and beyond. ABOUT IMMUNE-ONC THERAPEUTICS, INC. Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development, including IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for the treatment of acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). The company also plans to evaluate IO-202 in solid tumors in 1H2022. The U.S. Food and Drug Administration granted IO-202 Orphan Drug Designation for treatment of AML in 2020. Additional assets in Immune-Onc’s pipeline include IO-106, a first-in-class anti-LAIR1 antibody, and multiple undisclosed programs for solid tumors and hematologic malignancies. The company has strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center, and has invested in proprietary models, assays, and tools to interrogate the biology and translate this cutting-edge research into the development of novel therapies. Immune-Onc has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and a strategic investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit www.immune-onc.com and follow us on Twitter and LinkedIn . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Immune-Onc Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Immune-Onc Therapeutics is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Immune-Onc Therapeutics Patents

Immune-Onc Therapeutics has filed 5 patents.

The 3 most popular patent topics include:

  • Phenols
  • Autoimmune diseases
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/8/2018

6/30/2020

Piperazines, Hepatotoxins, Autoimmune diseases, Lactams, Phenols

Grant

Application Date

10/8/2018

Grant Date

6/30/2020

Title

Related Topics

Piperazines, Hepatotoxins, Autoimmune diseases, Lactams, Phenols

Status

Grant

Immune-Onc Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Immune-Onc Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.